Moderator
Sean D Sullivan, PhD, University of Washington, Seattle, WA, United States
Speakers
Olivia Wu, MSc, PhD, University of Glasgow, Glasgow, United Kingdom; Lynda Doward, MSc, RTI- Health Solutions, Manchester, United Kingdom; Nicholas Adlard, MA, MBA, MSc, Novartis Pharma, Basel, Switzerland
ISSUE: This panel will explore how Health Technology Assessment (HTA) will evolve over the next decade and what HTA may look like for innovative medicines entering early clinical trials today, undergoing HTA in 10 years’ time. Discussion topics include macroeconomic changes impacting the pharma business model for HTA, evolution of methods of assessment and appraisal, and opportunities for greater inclusion of the patient voice.
OVERVIEW: The complexity of HTA is growing, within the varying assessment disciplines of comparative clinical benefit, cost-effectiveness, and budget impact with increasing interest in other elements of the ISPOR value flower such as value of innovation, societal perspective, hope and equity. This complexity has fostered increasing collaboration between HTA agencies with formation of groupings such as EU HTA and HEMA, to develop more consistent and innovative methodologies.External environmental factors will also be considered such as how HTA deals with evolving cross-border collaborations, instability of global pricing landscape and the changing relationship between health authorities and HTAs.To remain fit for purpose, HTA will need to evolve while continuing to accommodate the diverse needs of patients, providers, industry and taxpayers, while accommodating a growing patient voice.An overview with be provided by Dr. Sullivan, approx. 5 minutes. He will outline the changing flow of influence between regulators and HTA bodies, and the potential impact of changes to the global pharma pricing model.Prof. Wu will offer perspectives on the evolution of HTA methods. Lynda Doward will outline how HTA can enable a more enriched and consistent embodiment of the patient voice. Nicholas Adlard will provide a manufacturer’s perspective. In conclusion, HTA must consider macroeconomic changes, while incorporating a consistent patient voice and reflecting national cultural identities and differing healthcare systems. Can HTA resolve these conflicts to offer systematic value assessment on a global level in the future?
Code
036
Topic
Economic Evaluation, Health Technology Assessment, Patient-Centered Research